Clinical studies of arsenic in treating other malignancies
| Disease . | Year . | Authors . | No. . | Regimen . | Response . |
|---|---|---|---|---|---|
| MM | 2006 | Berenson et al166 | 65 | ATO + AA + melphan | 2 CR; 15 PR; 14 MR |
| 2006 | Abou-Jawde et al167 | 20 | ATO + AA + dexamethasone | 6 PR | |
| 2006 | Wu et al168 | 20 | ATO + AA + dexamethasone | 2 PR; 6 MR | |
| 2007 | Berenson et al169 | 22 | ATO + AA + bortezomib | 2 PR; 4 MR | |
| ATL | 2004 | Hermine et al170 | 7 (Relapsed/refractory) | ATO + IFN | 1 CR; 3 PR |
| 2009 | Kchour et al171 | 10 (Newly diagnosed) | ATO + IFN + zidovudine | 9 CR; 1 PR | |
| MDS | 2006 | Schiller et al172 | 76 | ATO | 1 CR; 13 HI |
| 2006 | Vey et al173 | 115 | ATO | 1 CR; 1 PR; 22 HI | |
| 2008 | Zheng et al174 | 21 | ATO + RA + thalidomide | 1 CR; 1 PR; 3 HI | |
| Lymphoid malignancies | 2009 | Chang et al175 | 16 | ATO + AA | 1 response |
| Disease . | Year . | Authors . | No. . | Regimen . | Response . |
|---|---|---|---|---|---|
| MM | 2006 | Berenson et al166 | 65 | ATO + AA + melphan | 2 CR; 15 PR; 14 MR |
| 2006 | Abou-Jawde et al167 | 20 | ATO + AA + dexamethasone | 6 PR | |
| 2006 | Wu et al168 | 20 | ATO + AA + dexamethasone | 2 PR; 6 MR | |
| 2007 | Berenson et al169 | 22 | ATO + AA + bortezomib | 2 PR; 4 MR | |
| ATL | 2004 | Hermine et al170 | 7 (Relapsed/refractory) | ATO + IFN | 1 CR; 3 PR |
| 2009 | Kchour et al171 | 10 (Newly diagnosed) | ATO + IFN + zidovudine | 9 CR; 1 PR | |
| MDS | 2006 | Schiller et al172 | 76 | ATO | 1 CR; 13 HI |
| 2006 | Vey et al173 | 115 | ATO | 1 CR; 1 PR; 22 HI | |
| 2008 | Zheng et al174 | 21 | ATO + RA + thalidomide | 1 CR; 1 PR; 3 HI | |
| Lymphoid malignancies | 2009 | Chang et al175 | 16 | ATO + AA | 1 response |
MM indicates multiple myeloma; AA, ascorbic acid; CR, complete response; PR, partial response; MR, minor response; ATL, adult T-cell leukemia/lymphoma; MDS, myelodysplasia syndrome; HI, hematologic improvement; and RA, retinoic acid.